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Proteasomal degradationc-MYC is an oncogenic transcription factor that is degraded by the proteasome pathway. However, the
mechanism that regulates delivery of c-MYC to the proteasome for degradation is not well characterized. Here,
the results show that the motor protein complex Kinesin-1 transports c-MYC to the cytoplasm for proteasomal
degradation. Inhibition of Kinesin-1 function enhanced ubiquitination of c-MYC and induced aggregation of
c-MYC in the cytoplasm. Transport studies showed that the c-MYC aggregates moved from the nucleus to the
cytoplasmandKIF5B is responsible for the transport in the cytoplasm. Furthermore, inhibition of the proteasomal
degradation process also resulted in an accumulation of c-MYC aggregates in the cytoplasm.Moreover, Kinesin-1
was shown to interactwith c-MYC and the proteasome subunit S6a. Inhibition of Kinesin-1 function also reduced
c-MYC-dependent transformation activities. Taken together, the results strongly suggest that Kinesin-1 trans-
ports c-MYC for proteasomal degradation in the cytoplasm and the proper degradation of c-MYC mediated by
Kinesin-1 transport is important for transformation activities of c-MYC. In addition, the results indicate that
Kinesin-1 transport mechanism is important for degradation of a number of other proteins as well.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
c-MYC is a major regulator of diverse physiological processes, such
as proliferation, apoptosis, differentiation and genomic stability. In
addition, c-MYC causes cancer when it is overexpressed [1–3]. Hence,
the cellular levels of c-MYC are tightly regulated by multiple mecha-
nisms, including degradation by the ubiquitin–proteasome pathway
[4–6]. In this pathway, c-MYC is conjugated with polyubiquitin chains.
The ubiquitination of c-MYC serves as a signal for c-MYC degradation
by the proteasomal protein destruction machine.
Kinesins belong to a large family of intracellularmolecularmotors [7,
8]. Thesemolecularmotors hydrolyze ATP and convert the chemical en-
ergy to mechanical energy to move along microtubules and carry their
cargo, such as mRNA, membranous vesicles, organelles and protein
complexes, to their speciﬁc target places [7,9,10]. Defects in these
molecular motors give rise to various diseases, such as cancer, neuro-
degeneration and developmental defects [9,10]. Kinesin-1 is the
founding member of this superfamily and is a heterotetrameric protein
containing two subunits of Kinesin Light Chain 1 (KLC1) and two sub-
units of Kinesin Heavy Chain (KHC). KHC contains a motor domain to
hydrolyze ATP and move along microtubules, while KLC1 interactsythro-9-[3-(2-hydroxynonyl)]
1; DMSO, dimethyl sulfoxide;
ino-2-phenylindolewith cargoes [7]. There are three members of KHCs, namely KIF5A,
KIF5B and KIF5C [7]. While KIF5B is ubiquitously expressed, KIF5A and
KIF5C are neuronal speciﬁc [7].
It remains unclear how c-MYC is delivered to proteasomes for deg-
radation. Here, the results show that c-MYC is a cargo of Kinesin-1
and that Kinesin-1 is actively involved in transporting c-MYC for
proteasomal degradation in the cytoplasm.
2. Materials and methods
2.1. Materials
The following reagents were obtained commercially: anti-c-MYC
antibodies [sc764 and sc-70467 (Santa Cruz); 5605 (Cell Signaling)];
anti-HA antibody [sc-7392 and sc-805 (Santa Cruz)]; anti-V5 antibody
[sc-271944 and sc-83849-R (Santa Cruz)]; anti-GFP antibody [sc-9996
(Santa Cruz)]; anti-ubiquitin antibody [sc-8017 (Santa Cruz); 3933
(Cell Signaling)]; anti-p53 antibody [sc-126 (Santa Cruz)]; anti-NF-κB
p65 antibody [sc-8008 (Santa Cruz)]; anti-p38MAPK antibody [8690
(Cell Signaling)]; anti-c-Fos antibody [2250 (Cell Signaling)]; anti-
Rab8 antibody [6975 (Cell Signaling)]; anti-β-Actin antibody [A2228
(Sigma)]; anti-α-Tubulin [T9026 (Sigma)]; anti-KIF5B antibody
[21632-1-AP (Proteintech)]; anti-KLC1 antibody [sc-13362 (Santa
Cruz)]; anti-S6a antibody [PW8770 (Enzo)]; anti-S6b antibody
[PW8175 (Enzo)]; anti-Skp2 [sc-7164 (Santa Cruz)]; antibody anti-
CHIP antibody [PC711 (Calbiochem)]; MG132 (Boston Biochem);
pTagCFP-C (Evrogen); ptdTomato and pAcGFP (Clontech).
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HEK293T, COS7 andHeLawere grown inDulbecco'sModiﬁed Eagle's
medium (Corning Cellgro) supplemented with 10% fetal bovine serum
(Sigma, MO). Cell cultures were maintained at 37 °C with 5% CO2.
2.3. siRNA and shRNA
HeLa cells were treated with double-stranded RNA oligonucleotide
that targets the mRNA of human KIF5B (accession number: NM_
004521) as described [11]: sense, 5′-UGA AUU GCU UAG UGA UGA
AdTdT-3′. The control double-stranded RNA oligonucleotide against
ﬁreﬂy luciferase has the following sequences: sense, 5′-AUGAACGUGA
AUUGCUCAAdTdT-3′. All siRNAswere synthesized by ThermoScientiﬁc.
Lipofectamine 2000 (Invitrogen) was used to transfect cells. HeLa cells
were subjected to at least two rounds of plating/transfection with the
siRNAs to knockdown the KIF5B expression levels.
A retroviral vector expressing the shRNA against KIF5Bwasprepared
by annealing two oligonucleotides with the sense sequence (5′-CCGG
TGAATTGCTTAGTGATGAACTCGAGTTCATCACTAAGCAATTCATTTTTA
ATT-3′). The annealed oligonucleotide was cloned into the AgeI and
EcoRI sites of the lentiviral vector pLKO-Tet-On containing the H1
RNA promoter and a tetracycline-inducible operator [12]. A DNA
fragment containing the H1 RNA promoter, the tetracycline-inducible
operator and the oligonucleotide sequence was ampliﬁed from the
vector, blunt-ended and cloned into MSCVhph (Clontech).
2.4. Transient transfection
For plasmid transfection, cells were transfected using Lipofectamine
2000 (Invitrogen) or XtremeGene 9 (Roche) according to the manufac-
turers' instructions. The plasmid/transfection reagent complex was
formed in OptiMEM I (Invitrogen) and then added to cells. The
transfected cells were harvested for analysis one day later.
2.5. Western blot analysis
The cell lysates or immunoprecipitates were resolved by SDS-PAGE.
The resolved proteins were transferred onto nitrocellulose membranes,
whichwere blocked in Blocking Buffer for FluorescentWestern Blotting
(Rockland). Appropriate primary antibodies were added to the
membranes in the blocking buffer containing 0.1% Tween-20 at 4 °C
overnight. Membranes were washed three times with washing buffer
(PBS/0.1% Tween-20) before they were incubated with IRDye 680RD-
and IRDye800CW-conjugated secondary antibodies (Odyssey) at room
temperature for an hour. The membranes were washed three times
with the washing buffer and the immunoreactive protein bands were
detected by the Odyssey Infrared imaging system.
2.6. Immunoprecipitation
For association studies, transfected cells were lysed in NP40 lysis
buffer (0.5% NP40 in PBS) supplemented with 1 mM DTT, 6 mM NaF
and protease inhibitors. For immunoprecipitation of ubiquitinated pro-
teins, transfected cells were lysed in RIPA buffer [13] supplemented
with 6 mM NaF and protease inhibitors. Appropriate antibodies were
added to the cell lysates and incubated at 4 °C for 2 h before Protein G
beads (GE Healthcare) were added for another hour. The beads were
washed three timeswith the lysis buffer, resuspended in Laemmli buffer
and subjected to SDS-PAGE. RIPA lysis buffer was also used for the pull-
down assays of 6His-tagged proteins using nickel-agarose beads.
2.7. Immunoﬂuorescence
These studies were conducted similarly as described [14] using
speciﬁc antibodies as indicated. The nuclei of live and ﬁxed cells werestained with Hoechst 33342 (Hoechst) and 4′,6-diamidino-2-
phenylindole (DAPI), respectively. The cells were analyzed under a ﬂuo-
rescence microscope (Olympus IX71_Fluoview). Images were captured
using DP72 Olympus camera system and cellSens software. Magniﬁca-
tion is at 40× unless indicated otherwise.
2.8. Soft agar assay
The REF/MYC-Ras cells or cancer cells were plated in soft agar (0.3%)
in the presence of DMSOor rose bengal lactone (RBL; 40 μM). Theywere
maintained at 37 °C with 5% CO2. Fresh medium was added every four
to ﬁve days. Photographs were taken for the colonies 4 and 17 days
after plating, respectively. The infected REF/MYC-Ras cells were also
similarly plated in soft agar.
3. Results
3.1. The effects of the Kinesin-1 inhibitor RBL on c-MYC
To study the effects of Kinesin-1 on c-MYC, three different strategies
to inhibit Kinesin-1 were employed: 1) the KIF5B inhibitor rose bengal
lactone (RBL), which inhibits the interaction between Kinesin-1 and
microtubules [15], 2) small interfering RNA (siRNA) against KIF5B and
3) a truncated mutant of KIF5B that inhibits the wild-type KIF5B func-
tions. Treatment of cells with the Kinesin-1 inhibitor (RBL) [15] showed
decreased levels of endogenous c-Myc (64 kDa) with a corresponding
increase in high-molecular weight species (HMWS) in both HEK293T
and HeLa cells (Fig. 1A). Interestingly, RBL also induced HMWS forma-
tion ofα-Tubulin with an intense 140 kDa protein band (Supplementa-
ry Fig. 1). However, RBL did not induce HMWS formation of β-Actin
(Fig. 1A and Supplementary Fig. 1). The HMWS could be detected by
various speciﬁc antibodies against different epitopes of c-MYC (Fig. 1A
and Supplementary Fig. 1) and the effects of RBL were dose-
dependent (Supplementary Fig. 2). Furthermore, formation of HMWS
could only be observed following treatmentwith theKinesin-1 inhibitor
RBL, but not following treatment with the inhibitor of another motor
protein Dynein [erythro-9-[3-(2-hydroxynonyl)] adenine (EHNA)]
[16] (Supplementary Fig. 3). Because the motor proteins Kinesin-1
and Dynein are responsible for anterograde and retrogrademovements,
respectively [11,17–19], these results suggest that anterograde, but not
retrograde, movement by Kinesin-1 was involved in the formation of
the HMWS of c-MYC.
To determine whether the observed HMWS is, in fact, a
ubiquitinated form of c-MYC, HEK293T cells were transfected with
6His-tagged ubiquitin [20] and subsequently treated with vehicle
(DMSO) or RBL. After RBL treatment, 6His-tagged ubiquitinated
proteinswere pulled downusing nickel-agarose beads and the resulting
precipitates were analyzed using a c-MYC speciﬁc antibody to detect
ubiquitinated c-MYC. The results in Fig. 1B show that ubiquitination of
c-MYC was enhanced by treatment with RBL, indicating that Kinesin-1
is involved in the proteasomal degradation of c-MYC. Similar results
were obtainedwith exogenous HA-tagged c-MYC (Fig. 1C) and endoge-
nous c-MYC (Fig. 1D). c-MYC is ubiquitinated by several E3 ubiquitin
ligases, such as Skp2, CHIP, Fbw7 and Pirh2 [21–24]. Attempts were
made to identify the E3 ubiquitin ligases involved in the RBL-mediated
ubiquitination of c-MYC. Results in Supplementary Fig. 4A and B show
that ablation of Skp2 and CHIP enhanced the endogenous c-MYC levels
especially in HEK293T cells. However, ubiquitinated (HMWS) c-MYC
was not reduced, suggesting that the E3 ubiquitin ligases Skp2 and
CHIP are not involved in the RBL-mediated ubiquitination of c-MYC.
To determine the subcellular localization of ubiquitinated c-MYC, HeLa
cells were treated with DMSO or RBL and then fractionated into the
cytoplasmic and nuclear fractions. While the results do not rule out
the possibility of ubiquitination of c-MYC induced by RBL in the cyto-
plasm (Supplementary Fig. 5), they do show that ubiquitinated
(HMWS) c-MYC was found in both cytoplasmic and nuclear fractions,
Fig. 1. Kinesin-1 inhibitor RBL increases ubiquitinated c-MYC levels. A: HEK293T and HeLa cells were treated with DMSO or rose bengal lactone (RBL; 40 μM) for 16 h. Cell lysates were
prepared and endogenous levels of c-MYC and β-Actin were analyzed by western blot analysis using speciﬁc antibodies against c-MYC [5605 (Cell Signaling)] and β-Actin. The high
molecular-weight species (HMWS) of c-MYC is shown in the RBL-treated cells. B: HEK293T cells were transfected with 6His-tagged Ubiquitin (Ub) and then treated with DMSO or
RBL. The cell lysates from the treated cells were mixed with nickel-agarose beads to pull down 6His-tagged (ubiquitinated) proteins. The precipitates were analyzed by western blotting
using the speciﬁc antibodies against c-MYC. C: HEK293T cells were transfected with an empty vector (V) or a vector expressing the exogenous HA-tagged c-MYC. After transfection, the
cellswere treatedwith DMSOor RBL (40 μM) for 16 h. Cell lysateswere prepared and immunoprecipitatedwith theHA tag speciﬁc antibody. The lysates togetherwith the immunoprecipitates
were analyzed by western blot using speciﬁc antibodies against c-MYC (upper panel) and Ub (lower panel). The high molecular-weight species (HMWS) of c-MYC is indicated. D: Cells were
treated as described in C, except that endogenous c-MYC was immunoprecipitated with its speciﬁc antibody [sc-40 (Santa Cruz)]. All the experiments were repeated at least twice.
Fig. 2.RBL induces aggregation of c-MYC. HeLa cells were treatedwith DMSOor RBL for 18 h and then ﬁxed and probedwith a control antibody or c-MYC antibody togetherwith DAPI. The
cells were then examined under a ﬂuorescent microscope. The percentages of cells showing c-MYC aggregates in the cytoplasmwere scored and the results are presented as mean± SD
(N = 3). Total number of cells examined was greater than 900. Morphology of the cells is also shown (bright ﬁeld).
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nucleus and that ubiquitinated c-MYC was transported into the
cytoplasm.
To determine the effects of RBL on endogenous c-MYC at the cellular
level, immunoﬂuorescence studies were performed in HeLa cells, which
were treatedwith vehicle (DMSO) or RBL. Results in Fig. 2 show that the
endogenous c-MYC mainly appeared in the nucleus in DMSO-treated
cells; however, upon the RBL treatment, c-MYC aggregated in the cyto-
plasm, suggesting that Kinesin-1 regulates the subcellular localization of
c-MYC.
To determine whether the formation of HMWS is a general property
associated with RBL treatment, a panel of cytoplasmic and nuclear pro-
teins were analyzed in cells that have been treated with DMSO or RBL.
Results in Fig. 3 show that among the proteins examined, c-MYC, p53,
KIF5B and α-Tubulin were most affected by RBL, suggesting that
Kinesin-1 is also involved in their proteasomal degradation. However,
RBL treatment induced low levels of p38MAPK, NF-κB p65 and c-Fos
HMWS and β-Actin did not form any HMWS, indicating that
proteasomal degradation of these proteins is not regulated by Kinesin-1.
3.2. The effects of the dominant negative mutant of KIF5B on c-MYC
To conﬁrm that the above observationwas due to the speciﬁc inhibi-
tion of KIF5B by RBL, two additional strategies were employed to inhibit
KIF5B: overexpression of a KIF5B dominant negative mutant and a
siRNA against KIF5B. First, c-MYC was co-expressed with wild-type
KIF5B or a motorless KIF5B mutant that lacks the motor domain but re-
tains the ability to dimerize with wild-type KIF5B. To assess the role of
Kinesin-1 in regulating the subcellular localization of c-MYC, TagCFP-
c-MYC was co-expressed in HeLa cells with wild-type or motorless
tdTomato-tagged KIF5B mutant and live-cell ﬂuorescence microscopy
was performed to determine subcellular localization. The results in
Fig. 4A show that in HeLa cells, c-MYC andwild-typeKIF5Bmainly local-
ized in the nucleus and cytoplasm, respectively. However, themotorless
KIF5B mutant appeared as punctate or ﬁlamentous aggregates as
described previously [19]. Expression of the motorless KIF5B mutant
resulted in the appearance of a fraction of c-MYC in the cytoplasm,
whereby both proteins co-localized together, suggesting that KIF5B
regulates the subcellular localization of c-MYC (Fig. 4A). A similar phe-
notype was also observed in H1299 cells, suggesting that the regulation
of c-MYC subcellular localization induced byKIF5B is not unique toHeLa
cells (Supplementary Fig. 6). Aggregation of endogenous c-MYC was
also induced by the motorless KIF5B mutant, but not by the wild-type
KIF5B (Fig. 4B). On the other hand, expression of the motorless KIF5B
mutant did not induce any appearance of AcGFP-c-Fos in the cytoplasm
(Supplementary Fig. 7), indicating that inhibition of KIF5B functionFig. 3. RBL increases the formation of HMWS of cytoplasmic and nuclear proteins. HEK293T cel
were analyzed by western blotting with speciﬁc antibodies against c-MYC, p53, NF-κB p65, KIF
The signals of the unmodiﬁed speciﬁc proteins in the DMSO- or RBL-treated samples were quan
the cells before they were treated with DMSO or RBL. All the experiments were repeated at leaspeciﬁcally affects certain transcription factors. In addition, expression
of the neuronal motorless KIF5A mutant also formed aggregates in the
cytoplasm, but failed to induce the aggregates of c-MYC in the cyto-
plasm (Supplementary Fig. 8). This further shows that KIF5B is the spe-
ciﬁcmotor transporter of c-MYC in these cells. In addition, themotorless
KIF5B mutant induced aggregation of part of the α-Tubulin network,
but not that of β-Actin, suggesting that KIF5B preferentially disrupts
part of the cytoskeletal organization of α-Tubulin (Supplementary
Fig. 9). Moreover, the motorless KIF5B mutant did not induce any
change in the subcellular localization of the Rab8 GTPase, suggesting
that KIF5B is not involved in the vascular trafﬁc between the trans-
Golgi network and basolateral membrane of the Rab8 GTPase (Supple-
mentary Fig. 10) [25]. Together, the data suggest that KIF5B is a speciﬁc
regulator of c-Myc transport.
3.3. The direction of transport of c-MYC mediated by KIF5B
To determine the direction of c-MYC transport, cells expressing
TagCFP-c-MYC and tdTomato-wild-type and motorless KIF5B mutant
were treated with the nuclear export inhibitor leptomycin B (LMB)
[26]. The results in Fig. 4C show that LMB treatment prevented c-MYC,
but not the motorless KIF5B mutant, from forming aggregates in the
cytoplasm. In contrast, in the DMSO control, both c-MYC and motorless
KIF5B formed aggregates in the cytoplasm. This result shows that c-MYC
is transported from the nucleus to the cytoplasm and that the c-MYC
aggregates are not derived from the newly synthesized pool of c-MYC
in the cytoplasm. Because KIF5B is an anterograde motor, moving on
microtubule originating from the microtubule organizing center in the
perinuclear region to the cell periphery [27,28], this result suggests
that KIF5B is responsible for the transport of c-MYC in the cytoplasm
during the process.
3.4. Co-localization of c-MYC and KIF5B in the cytoplasm
To show the association between c-MYC and KIF5B in the cell, im-
munoﬂuorescence studies were performed in HeLa cells expressing
HA-tagged c-MYC and tdTomato-tagged KIF5B. The results in Fig. 5
show that, upon high magniﬁcation (100×), tdTomato-tagged KIF5B
mainly appeared in a punctate distribution in the cytoplasm andmajor-
ity of HA-tagged c-MYC appeared in the nucleus. A longer exposure
shows that HA-c-MYC could be detected as ﬁne spots in the cytoplasm.
Some co-localized with tdTomato-KIF5B in the cytoplasm, suggesting
that c-MYC and KIF5B move together as a complex in the cytoplasm
for degradation. It is worth noting that some c-MYC punctations did
not co-localizewith tdTomato-KIF5B and thismay represent newly syn-
thesized c-MYC in the cytoplasm. To further show that KIF5B is involvedls were treated with DMSO or RBL (40 μΜ) for 16 h. The cell lysates from the treated cells
5B, p38MAPK,α-Tubulin and β-Actin. The molecular weight markers in kDa are indicated.
titated and their relative levels are quoted. For c-Fos, exogenous proteinwas expressed in
st twice.
Fig. 4. Expression of the motorless KIF5B mutant induces c-MYC appearance in the cytoplasm. A: HeLa cells were transfected with tdTomato-tagged wild-type (WT) or motorless KIF5B
mutant together with TagCFP-c-MYC. 18 h after transfection, theywere stainedwith the DNA intercalating dye Hoechst and then examined under a ﬂuorescencemicroscope. The percent-
ages of cells showing aggregates of CFP-c-MYC are shown. The results are presented asmean± SD (N=3). Total number of cells examinedwas greater than 370. B: Cells were transfected
with the WT or motorless tdTomato-KIF5B mutant. 18 h later, the cells were ﬁxed and probed for the endogenous c-MYC using its speciﬁc antibody and the DNA intercalating dye DAPI.
They were then examined under a ﬂuorescence microscope. The percentages of transfected cells showing c-MYC aggregates were scored and the results are presented as mean ± SD
(N = 3). Total number of cells examinedwas greater than 400. C: Cells were transfected with theWT ormotorless tdTomato-KIF5Bmutant together with TagCFP-c-MYC. 8 h after trans-
fection, cells were treated with vehicle (DMSO) or the nuclear export inhibitor leptomycin B (LMB) (100 ng/ml). 16 h after the LMB treatment, the cells were stainedwith the DNA inter-
calating dye Hoechst and then examined under a ﬂuorescence microscope. Proteins tagged with tdTomato and TagCFP appear red and blue, respectively. Co-localization of proteins with
both tags appears pink. Thepercentages of cells showing aggregates of CFP-c-MYC are shown. The results are presented asmean±SD (N=3). Total number of cells examinedwas greater
than 1500.
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cells was deprived of serum for 60min before analysis since serum dep-
rivation is known to induce degradation of c-MYC [29]. Results in Fig. 5
show that a higher amount of c-MYC appeared in the cytoplasm when
the cells were deprived of serum, suggesting that degradation of c-MYC
happens in the cytoplasm. Moreover, a high percentage of c-MYC in the
cytoplasm under this condition co-localized with KIF5B, suggesting that
these proteins form complexes and the complex formation is involved
in c-MYC degradation.3.5. The effects of the siRNA against KIF5B on c-MYC
To further conﬁrm the speciﬁc inhibition of KIF5B by RBL, the ex-
pression of KIF5B was knocked-down using a KIF5B-speciﬁc siRNA
(siKIF5B) (Fig. 6A) [30]. The results in Fig. 6B show that ablation of
KIF5B expression by siKIF5B induced accumulation of c-MYC aggregates
in the cytoplasm, while no c-MYC aggregated in the cytoplasm when
the cells were treated with the control siRNA, indicating that KIF5B is
important in transporting c-MYC in the cytoplasm.3.6. Aggregation of c-MYC and KIF5B in the cytoplasm induced by inhibition
of proteasomal degradation of c-MYC
To conﬁrm the involvement of Kinesin-1 in transporting c-MYC for
proteasomal degradation, cells expressing TagCFP-c-MYC and tdTomato-
wild-type KIF5B were treated with a proteasomal inhibitor MG132
[31]. The results in Fig. 7 show that inhibition of c-MYC degradation
by MG132 also induced aggregation and co-localization of the wild-
type KIF5B and c-MYC in the cytoplasm. Therefore, perturbation of
proteasomal degradation process results in an accumulation of c-MYC
in the cytoplasm, leading to formation of cytoplasmic aggregates.
Together, the data strongly indicate that c-MYC is transported to the
cytoplasm by KIF5B for proteasomal degradation.3.7. Association between c-MYC and Kinesin-1
Kinesin-1 is a heterotetramer consisting of two subunits of KIF5B
and two subunits of KLC1 [7]. The N-terminal motor domain of KIF5B
interacts with and moves along a microtubule, and the C-terminal
Fig. 5. Co-localization of c-MYC and KIF5B in the cytoplasm. HeLa cells were transfectedwith an expression vector for tdTomato-KIF5B together with an empty vector (V) or an expression
vector for HA-tagged c-MYC. 18 h after transfection, a set of cells was deprived of serum (−serum) for 60min. The cells were then ﬁxed and stainedwith the speciﬁc antibody against the
HA tag. The stained cells in the rightmost panel were examined under a ﬂuorescent microscope using the 60× objective. The signals of the HA-tagged c-MYC are overexposed to show
c-MYC appearance in the cytoplasm. The areas indicated by boxes in the rightmost panel were shown at the 100× magniﬁcation. Overlapping c-MYC and KIF5B are indicated by arrows
in the middle panel, while the overlapping of the two proteins in the bottom panel is too numerous to be indicated. HA-c-MYC and tdTomato-KIF5B appear green and red, respectively.
Co-localization of proteins with both tags appears orange. The percentages of c-MYC dots overlapping with KIF5B were scored and the results are presented as mean ± SD (N= 3).
2032 C.M. Lee / Biochimica et Biophysica Acta 1843 (2014) 2027–2036coiled-coil domain interacts with KLC1. It is KLC1 that interacts with the
scaffolding protein/cargo complexes [32]. To examine whether c-MYC
interacts with Kinesin-1, immunoprecipitation studies were
performed using cell lysates from transfected HEK293T cells expressing
V5-tagged c-MYC with or without tdTomato-tagged KIF5B. tdTomato-
tagged KIF5B was immunoprecipitated using the antibody against
tdTomato. The immunoprecipitates and lysates were then analyzed by
western blotting using antibodies against c-MYC and tdTomato. The re-
sults show that tdTomato-KIF5B could be co-immunoprecipitated with
V5-c-MYC (Fig. 8A), indicating that c-MYC and KIF5B interact. A similar
experimentwas performed in cells expressingV5-tagged c-MYCwith or
without HA-tagged KLC1. HA-tagged KLC1 was precipitated using an
antibody directed against the HA-tag. The immunoprecipitates and ly-
sates were then analyzed by western blotting using antibodies againstFig. 6.Ablation of KIF5B induces aggregation of c-MYC in the cytoplasm. A: HeLa cells were tran
were lysed for western blotting using the KIF5B and β-Actin antibodies. B: The siRNA-transfect
were ﬁxed and probed using speciﬁc antibodies against KIF5B (green), HA tag (red) and the DN
percentages of cells showing aggregates of HA-c-MYC are shown. The results are presented asHA-tag and c-MYC. The results show that V5-c-MYC could be co-
immunoprecipitated with HA-KLC1 (Fig. 8B), suggesting that c-MYC
and KLC1 interact with each other. Together, the results suggest that
c-MYC interacts with the Kinesin-1 complex (KIF5B/KLC1). The domain
of KLC1 that interactswith c-MYCwasmapped by immunoprecipitation
studies using the wild-type (WT) or deletion mutants (TPR1 or TPR2)
of HA-tagged KLC1. The results in Fig. 8C show that deletion of the
N-terminal coiled-coil domain of KLC1 abolished the association of
KLC1 and c-MYC, indicating that the N-terminus of KLC1 is important
in the interaction with c-MYC. To further illustrate the importance of
the N-terminal region of KLC1 in binding c-MYC, immunoprecipitation
studies using the HA-tagged N-terminal region of KLC1(CC) and V5-
tagged c-MYC were performed. Immunoprecipitation of KLC1(CC)
using the HA antibody could co-precipitate c-MYC (Fig. 8D), indicatingsfectedwith a control siRNA or the siRNA against KIF5B (siKIF5B). Nine days later, the cells
ed cells were also transiently transfected to express HA-tagged c-MYC. 18 h later, the cells
A intercalating dye DAPI. They were then examined under a ﬂuorescence microscope. The
mean ± SD (N= 3). Total number of cells examined was greater than 1200.
Fig. 7. Proteasomal inhibitor MG132 induces aggregation of KIF5B and c-MYC in the cytoplasm. HeLa cells were transfected to express TagCFP-tagged c-MYC together with tdTomato-
tagged KIF5B. 8 h after transfection, the cells were treated with DMSO or the proteasome inhibitor MG132 (4 μM). 18 h after transfection, they were stained with the DNA intercalating
dye Hoechst and then examined under a ﬂuorescencemicroscope. The percentages of cells showing aggregates of CFP-c-MYC are shown. The results are presented asmean± SD (N=3).
Total number of cells examinedwas greater than 600. tdTomato-KIF5B and TagCFP-c-MYC appear red and blue, respectively. Pink color indicates co-localization of proteinswith both tags.
Fig. 8. Interaction of Kinesin-1 with c-MYC and the proteasome subunit S6a. A: HEK293T cells were transfected with an expression plasmid for V5-c-MYC together with an empty vector
(V) or an expression vector for tdTomato-KIF5B. Cell lysates were prepared from the transfected cells for immunoprecipitation using the tdTomato antibody. The lysates and immunopre-
cipitateswere analyzed bywestern blotting using the c-MYC and tdTomato antibodies. B: Cells were transfectedwith an empty vector (V) orHA-tagged KLC1 expression plasmid together
with V5-tagged c-MYC. Cell lysates from the cells were immunoprecipitated with the antibody against HA-tag. The immunoprecipitates and lysates were analyzed by western blotting
using antibodies against HA-tag and c-MYC. C: The upper panel shows a diagrammatic representation of wild-type (WT) KLC1 or its deletion mutants (CC, TPR1 and TPR2). The lower
panel shows the immunoprecipitation studies as described in A using cells transfected with V5-tagged c-MYC and HA-tagged KLC1 proteins. D: The association study between the V5-
tagged c-MYC and theN-terminal of KLC1 (CC; amino acids: 1–221)was performed as in C. E: Cell lysate fromHEK293T cells was immunoprecipitatedwith a control antibody or a speciﬁc
antibody against KLC1. The lysate and the immunoprecipitateswere analyzed bywestern blotting using the antibodies against c-MYC and KLC1. F: HEK293T cells were transfectedwith an
empty vector (V) or an expression plasmid for the V5-tagged proteasome subunit S6a together with a plasmids for the HA-tagged KLC1 proteins. Cell lysates from the transfectants were
immunoprecipitatedwith the anti-V5 antibody.Western blot analysiswas performed on the immunoprecipitates togetherwith the cell lysates using the antibodies against V5 andHA. G:
The association study between the V5-tagged S6a and KLC1(CC) was conducted as in F. The transfected cells were treated with MG132 (10 μM) for 4 h to stabilize the CC protein levels
before cell lysates were prepared for the association studies. H: HEK293T cell lysate was immunoprecipitated with a control antibody or the KLC1 antibody. The lysate and immunopre-
cipitates were analyzed by western blotting using the antibodies against S6ba, S6b and KLC1. All the experiments were repeated at least twice.
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is involved in binding to c-MYC. The formation of the c-MYC/KLC1
complex was substantiated by immunoprecipitation studies of the
endogenous proteins. HEK293T cell lysates were immunoprecipitated
with a control antibody or a speciﬁc antibody against KLC1. The KLC1
immunoprecipitate, but not the control immune-precipitate, was
found to contain c-MYC (Fig. 8E). Together, the results show that
c-MYC and KLC1 associate to form a complex.
3.8. Association between KLC1 and the proteasome subunit S6a
To examine whether Kinesin-1 also interacts with the proteasome,
HEK293T cells were transfected with an empty vector or an expression
plasmid encoding the V5-tagged proteasome subunit S6a [33] together
with thewild-type, TPR1 or TPR2 of theHA-taggedKLC1. S6a is involved
in interacting with incoming protein p53 for proteasomal degradation
[33]. It is possible that the motor protein KLC1 that delivers c-MYC for
degradation may also interact with S6a. After transfection, cell lysates
were prepared and immunoprecipitated with the V5 antibody. The
immunoprecipitates and the lysates were then subjected to western
blot analysis. The results in Fig. 8F show that the proteasome subunit
S6a associated with WT KLC1, but not with the KLC1 mutants TPR1
and TPR2, indicating that S6a interacts with the N-terminal region of
KLC1 and that Kinesin-1 may be delivering its cargoes to the protea-
some for degradation. To further show the importance of the
N-terminal region of KLC1 in binding S6a, immunoprecipitation studies
were conducted with cell lysates expressing the HA-tagged CC of KLC1
with or without V5-tagged S6a. Results in Fig. 8G show that immuno-
precipitation of V5-S6a could pull down HA-CC, suggesting that theFig. 9. Inhibition of Kinesin-1 reduces transformation activities of REF/MYC-Ras cells. A: REF/MY
their colonieswere taken 4 days after plating. Scale bar, 100 μm. Colonies bigger than 50 μmwe
grown in culture dishes is shown. The percentages of ﬁbroblast-like cells were scored and the re
ence of DMSOor RBL. The total number of cellswas determined each day and the average numb
or shKIF5B. Western blotting results of the infected cells are shown. Similar experiments were p
(F). Scale bar in E, 200 μm. All the experiments were repeated at least three times.N-terminal region of KLC1 containing the coiled-coil domain is involved
in binding S6a. The complex formation between KLC1 and S6a was
further shown by immunoprecipitation studies using the endogenous
proteins. HEK293T cell lysates were immunoprecipitated with a control
antibody or a speciﬁc antibody against KLC1. The KLC1 immunoprecip-
itate, but not the control, was found to co-precipitate S6a (Fig. 8H),
showing that KLC1 and S6b interact in vivo. In addition, another endog-
enous proteasomal subunit S6b was also found to associate with KLC1
using a similar association study (Fig. 8H).
3.9. The effects of Kinesin-1 inhibition on transformation activities of c-MYC
To examine the biological effects of Kinesin-1 inhibition on transfor-
mation, anchorage-independent growth of rat embryonic ﬁbroblasts
(REFs) transformed co-operatively by exogenous c-MYC and activated
H-Ras (REF/MYC-Ras cells) [34] was examined. The cells were seeded
in soft agar with DMSO or RBL and permitted to grow until colonies
appeared. The results in Fig. 9A show that RBL inhibited the
anchorage-independent growth of the cells while the DMSO-treated
cells grew into colonies within four days, suggesting that Kinesin-1
function and c-MYC ubiquitination/degradation are necessary for trans-
formation mediated by c-MYC. Focus-forming assays were also
performed to further show the effects of Kinesin-1 inhibition on trans-
formation mediated by c-MYC. The REF/MYC-Ras cells were plated in
culture dishes in the presence of DMSO or RBL. The DMSO-treated
cells formed foci, while the RBL-treated cells became more ﬁbroblast-
like andﬂat (Fig. 9B), indicating that inhibition of Kinesin-1 also reduces
focus-forming ability by c-MYC. The inhibition was not due to non-
speciﬁc cell death induced by RBL because when the growth rate ofC-Ras cellswere plated in soft agar in the presence of DMSOor RBL (40 μM). Photographs of
re scored and the results are presented asmean± SD. B:Morphology of REF/MYC-Ras cells
sults are presented asmean± SD. C: REF/MYC-Ras cells were seeded on day 0 in the pres-
er has beenplotted. D: REF/MYC-Ras cellswere infectedwith retrovirus for a control shRNA
erformed as in B and C with the infected cells grown in soft agar (E) and in culture dishes
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ed cells, although a noticeable reduction in their growth ratewas appar-
ent from the third day of the incubationwith RBL (Fig. 9C). Furthermore,
similar inhibition of transforming activities by RBL was also observed
in 5 additional cancer cell lines originating from various tumor types
(Supplementary Fig. 11).
To conﬁrm reduction of transformation activities of c-MYC by
inhibiting Kinesin-1, REF/MYC-Ras cells were infected to express the
shRNA against KIF5B (shKIF5B) or the control shRNA. The infected
cells were selected by hygromycin and then seeded for soft agar assays.
Western blotting results in Fig. 9D show that shKIF5B reduced KIF5B in
REF/MYC-Ras cells, compared with that in the control shRNA-treated
cells. The results in Fig. 9E show that ablation of KIF5B reduced the
anchorage-independent growth of the cells while the control shRNA-
treated cells grew into colonies within four days, conﬁrming that
KIF5B is necessary for transformation mediated by c-MYC. Focus-
forming assays were also performed to further show the effects of
Kinesin-1 inhibition on transformation mediated by c-MYC. The REF/
MYC-Ras cells infected with shKIF5B or the control shRNA were plated
in culture dishes. The control shRNA-treated cells formed foci, while
the shKIF5B-treated cells became more ﬁbroblast-like and ﬂat
(Fig. 9F), indicating that ablation of KIF5B also reduces focus-forming
ability by c-MYC. Together, the results show that KIF5B is important
for transformation mediated by c-MYC.
4. Discussion
To date, this is the ﬁrst report that describes the following: c-MYC is
a cargo of Kinesin-1, the proteasome is one of the Kinesin-1 destinations
and Kinesin-1 is important in transporting c-MYC for proteasomal deg-
radation in the cytoplasm. When the transport of ubiquitinated c-MYC
is inhibited, c-MYC forms aggregates in the cytoplasm, suggesting that
the nuclear transcription factor c-MYC is actively transported by
Kinesin-1 to the proteasome for degradation in the cytoplasm. This con-
stitutes a previously undiscovered layer of post-translational regulation
of c-MYC at the protein level by Kinesin-1. Furthermore, the results sug-
gest that the transport direction is from the nucleus to the cytoplasm,
which is further supported by the experiments using the nuclear export
inhibitor leptomycin B (Fig. 4C). These results are consistent with the
anterograde transport of Kinesin-1. In general, microtubules are
arranged with their minus ends clustered around the microtubule
organizing center near the nucleus and their plus ends pointing toward
the cell periphery [27]. Kinesin-1 is a plus-end-directed motor that
moves from the perinuclear region toward the plus ends of microtu-
bules in the cell periphery [9,27,28,35]. Therefore Kinesin-1 is responsi-
ble for the transport of c-MYC in the cytoplasm, while another
unidentiﬁed mechanism is responsible for transporting c-MYC out of
the nucleus. Fig. 3 shows that other nuclear and cytoplasmic proteins
formed HMWS when the cells were treated with RBL, suggesting that
the transport mediated by Kinesin-1 is a more general mechanism
employed by some proteins for their proteasomal degradation. It
is worth noting that c-Fos shows weak formation of HMWS upon
RBL treatment (Fig. 3) and it did not show any aggregation in the
cytoplasm when the KIF5B motorless mutant was co-expressed
(Supplementary Fig. 7), suggesting that c-Fos is not degraded in
the cytoplasm via the KIF5B-dependent mechanism. It is possible
that c-Fos is degraded in the nucleus or in the cytoplasm via another
transport mechanism.
Proteasomes are distributed in the nucleus and in the cytoplasm,
where some are associated with the endoplasmic reticulummembrane
[36,37]. Proteasomal degradation occurs in those subcellular compart-
ments. It is intriguing to ﬁnd that the nuclear factor c-MYC is degraded
in the cytoplasm although the c-MYC ubiquitin ligases (Fbw7 isoforms)
are found in the nucleus [24]. In the current study, more c-MYC/KIF5B
complexes were formed in the cytoplasm when c-MYC was induced
for degradation by serum deprivation (Fig. 5), indicating that thecytoplasm is an important site for c-MYC degradation. Furthermore, it
is shown that ubiquitinated c-MYC induced by RBL is found in both
the nucleus and cytoplasm (Supplementary Fig. 5). It suggests that c-
MYC is ubiquitinated in the nucleus and then exported to the cytoplasm
for degradation or degradation of c-MYC occurs in the nucleus and
cytoplasm. It has been reported that the transcription factor p53, a
short-lived protein, is also transported from the nucleus to the cyto-
plasm for proteasomal degradation [38,39]. Interestingly, p53
also forms HMWS upon RBL treatment (Fig. 3), suggesting that p53,
like c-MYC, is also degraded in the cytoplasm through the KIF5B-
dependent mechanism. It is also interesting to note that the other com-
ponents of the transport system KIF5B and α-Tubulin also form HMWS
upon RBL treatment (Fig. 3).
It is possible that c-MYC is degraded in the cytoplasmbecause c-MYC
is not properly recognized or accessible by the nuclear or nucleolar
proteasomes under certain conditions. Alternatively, it may be faster
to export c-MYC out of the nucleus to reduce c-MYC function. It is
worth noting that, in addition to the cytoplasmic proteasomal system,
the lysosomal system alsomediates protein degradation [40–42]. How-
ever, when Kinesin-1 is inhibited, c-MYC still forms aggregates in the
cytoplasm that are not cleared by the lysosomal degradation system,
suggesting that the anterograde motor Kinesin-1 is also involved in
the lysosomal degradation.
Fig. 3 shows that there are two groups of proteins exhibiting differ-
ent responses to RBL-mediated HMWS formation. One group of pro-
teins, like c-MYC, p53, KIF5B and α-Tubulin, is sensitive to RBL. Within
this group, c-MYC and p53 are nuclear transcription factors, while
KIF5B and α-Tubulin are mainly cytoplasmic proteins. Both c-MYC as
shown in this report and p53 are degraded in the cytoplasm [38,39].
Another group of proteins, p38MAPK, NF-κB p65, β-Actin and c-Fos, is
not sensitive to RBL. Within this group, in unstimulated cells,
p38MAPK andNF-κB p65 localize in the cytoplasm,while c-Fos localizes
in the nucleus and β-Actin in both compartments. There is no obvious
correlation between the subcellular location of a protein and RBL-
mediated HMWS formation. The proteins in the latter group may or
may not be degraded via the KIF5B-dependent mechanism, although
their degradation rates are slow.
The results here show that KIF5B and KCL1 interact with c-MYC. In-
terestingly, KLC1 interacts with the scaffolding protein JLP [43], which
has been shown to associate with c-MYC [14]. Therefore it is possible
that JLP serves as an adapter to bring Kinesin-1 and c-MYC together.
This is consistent with the ﬁndings that Kinesin uses JLP as an adapter
protein to transport its cargo (endosomal vehicles) for microtubule-
based endosome-to-trans-Golgi network trafﬁc [44].
c-MYC and Kinesin-1 are related to cancer formation. Although the
role of c-MYC in cancer is well established [3], the role that Kinesin-1
plays in tumor formation is not well characterized. Kinesin-1 mRNA
and protein levels are elevated in several tumor types and cancer cell
lines [8]. Furthermore, ablation of KIF5B shows various degrees of cyto-
toxicity toward cancer cells [45]. While it is advantageous for cancer
cells to maintain high levels of c-MYC for cancer phenotypes [1,2], it is
not known why cancer cells require Kinesin-1, if Kinesin-1 transports
c-MYC to proteasomes for elimination. It is possible that Kinesin-1 is im-
portant to eliminate c-MYC ‘waste’. High levels of c-MYC in cancer cells
lead to the production of high levels of c-MYC ‘waste’ to be degraded. If
the ubiquitinated c-MYC ‘waste’ is not cleared fast enough, it will form
aggregates [46,47]. The effects may be similar to the aggregation of
c-MYC in the cytoplasm induced by MG132 or RBL (Figs. 2 and 7). It is
known that protein aggregates are toxic to the cells [48]. As a result, can-
cer cells have a higher dependency on Kinesin-1 to eliminate the c-MYC
‘waste’ to avoid its aggregation and the associated cytotoxicity. Further-
more, when the degradation of c-MYC is inhibited, c-MYC is accumulat-
ed in the cells, leading to the inhibition of its transformation activities
(Fig. 9). Therefore, cancer cells also depend on Kinesin-1 to maintain
the transformation activities of c-MYC. The ﬁndings show that
Kinesin-1 is essential for proper c-MYC degradation and its
2036 C.M. Lee / Biochimica et Biophysica Acta 1843 (2014) 2027–2036transformation activities. The dependence of cancer cells on Kinesin-1
makes Kinesin-1 an attractive therapeutic target for treatments.
In addition to its involvement in cancer formation, Kinesin-1 may
have a role in neurodegenerative diseases. Kinesin-1 has been shown
to transport proteins such as Tau and α-Synuclein that are implicated
in the pathology of neurodegenerative diseases [49]. Both proteins
form aggregates in neuronal cells. It will be interesting to determine
whether Kinesin-1 also transports them to proteasomes for degradation
and whether Kinesin-1 plays a role in aggregate formation of Tau and
α-Synuclein proteins in the brain.
Taken together, this report links the intracellular motor Kinesin-1,
c-MYC and proteasomal degradation. Kinesin-1 serves as a regulator
regulator/molecular motor in the transport of c-MYC to proteasomes
for degradation. Blocking of Kinesin-1 function will lead to hyper-
ubiquitination and aggregation of c-MYC in the cytoplasm resulting in
inhibition of transformation activities of c-MYC. Therefore, Kinesin-1
adds another layer of post-translational control of c-MYC and may pro-
vide an avenue for therapeutic intervention for c-MYC-mediated
cancers.
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